Living with multiple sclerosis means facing a condition that can cause unpredictable changes in the body. For people newly diagnosed, finding a reliable treatment to slow down disease activity is a top priority. A recent trial compared two specific medications, rituximab and ocrelizumab, to see how they performed over a 24-month period.
The study focused on adults with new relapsing multiple sclerosis. The results showed that both drugs were highly effective at preventing new or growing lesions on MRI scans. Specifically, 92.2% of patients on rituximab and 94.8% of those on ocrelizumab showed no new lesions between months 6 and 24. Other factors, like relapse rates and cognitive performance, remained similar for both groups.
Safety is a major consideration when choosing a treatment path. While both drugs had similar rates of serious side effects (8% for rituximab and 7% for ocrelizumab), infections were more common in the group receiving rituximab. Because these results are based on MRI findings rather than clinical outcomes as the primary measure, talk to your doctor to see which option fits your specific needs.
